Induction of apoptosis by proteasome inhibitor MG-132 in human erythroleukemia cell line K562.
- Author:
Xi-Ge WANG
1
;
Qing-Fei HAO
;
You-Cai TANG
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; pharmacology; Apoptosis; drug effects; Caspase 3; metabolism; Cysteine Proteinase Inhibitors; pharmacology; Dose-Response Relationship, Drug; Humans; K562 Cells; Leupeptins; pharmacology; NF-kappa B; Proteasome Inhibitors; Reverse Transcriptase Polymerase Chain Reaction
- From: Chinese Journal of Contemporary Pediatrics 2009;11(4):255-258
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate whether proteasome inhibitor MG-132 induces apoptosis of human erythroleukemia cell line K562 and possible mechanisms.
METHODSK562 cells were incubated with RPMI 1640 and exposed to 0, 1, 5, 10, 15 micromol/L of MG-132 for 24 hrs, respectively. The apoptosis of cells were detected by fluorescence microscope, DNA fragments and flow cytometry. The NF-kappaB mRNA expression was quantified by reverse transcription-polymerase chain reaction (RT-PCR). Expression of NF-kappaB and caspase-3 was semiquantitatively analyzed with SABC techniques. Caspase-3 activities were measured with a colorimetric method.
RESULTSThe growth of K562 cells was inhibited and the apoptosis of the cells increased after MG-132 treatment in a dose-dependent manner. After 24 hrs of 15 micromol/L MG-132 treatment, the percentage of apoptotic cells (26.5+/-0.6%) increased significantly when compared with the untreated controls (1.2+/-0.1%) (P<0.01). MG-132 treatment decreased the mRNA and protein expression of NF-kappaB, and increased the protein expression of caspase-3.
CONCLUSIONSMG-132 can induce apoptosis of human erythroleukemia cell line K562 through the down-regulation of NF-kappaB expression and up-regulation of caspase-3 expression.
